Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir

Journal of Medical Virology

Volumn 76, Issue 4, 2005, Pages 447-451

  Svedhem, Veronica ^a   Lindkvist, A ^b   Bergroth, T ^b   Knut, Lidman ^a   Sonnerborg A ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Mutation; NFV; Subtype; Therapy failure; Wild type virus

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; RNA SEQUENCE; SWEDEN; TREATMENT FAILURE; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; NELFINAVIR; RNA, VIRAL; SWEDEN; TREATMENT FAILURE; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 21744450290     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20381     Document Type: Article

References (32)

1. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. 2003. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 33:336-342.
2. Birk M, Sonnerborg A. 1998. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS 12:2369-2375.
3. Birk M, Svedhem V, Sonnerborg A. 2001. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 15:1359-1368.
4. Clotet B, Ruiz L, Martinez-Picado J, Negredo E, Hill A, Popescu M. 2002. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: A retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials 3:316-323.
5. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71:1089-1096.
6. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. 2003. Drug resistance mutations in HIV-1. Top HIV Med 11:92-96.
7. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 179:1375-1381.
8. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5:41-48.
9. Dronda F, Casado JL, Moreno S. 2001. Phenotypic crossresistance to nelfinavir: The role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res Hum Retroviruses 17: 211-215.
10. EACS. 2003. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS XX: S3-S26.
11. Gallego O, Ruiz L, Vallejo A, Ferrer E, Rubio A, Clotet B, Leal M, Soriano V, Group E. 2001. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 15:1894-1896.
12. Gulick JM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739.
13. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF, Richman DD, Wong JK. 2001. Prevalence and predictive value of intermittent viremia with combination hiv therapy. AMA 286:171-179.
14. Hirsch M, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, D'Aquila R, Demeter L, Hammer S, Johnson V, Loveday C, Mellors J, Jacobsen D, Richman D. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37:113-128.
15. Lucas GM, Chaisson RE, Moore RD. 1999. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131:81-87.
16. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73:3744-3752.
17. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
18. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
19. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133:21-30.
20. Patick A, Duran M, Cao Y, Shugarts D, Keller M, Mazabel E, Knowles M, Chapman S, Kuritzkes D, Markowitz M. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 42:2637-2644.
21. Perez G, MacArthur R, Walmsley S. 2002. A multinational randomized clinical endpoint study comparing nelfinavir and ritonavir in 775 patients (CPCRA 042/CTN 102) for the Terry Beirn Community Programs for Clinical Research on AIDS and the Canadian HIV Trials Network.; November 17-21.; Glasgow: United Kingdom.
22. Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Munoz-Fernandez M, Babiker A. 2002. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186:617-625.
23. Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J. 2003. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Med 4:38-47.
24. Saah A, Haas D, DiNubile M, Chen J, Holder D, Rhodes R, Shivaprakash M, Bakshi K, Danovich R, Graham D, Condra J. 2003. Treatment with indinavir, efavirenz and adefovir after failure of nelfinavir therapy. J Infect Dis 187:1157-1162.
25. Shafer RW, Kantor R, Gonzales MJ. 2000. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev 2:211-228.
26. Sharma PL, Crumpacker CS. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 71:8846-8851.
27. Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, Hughes M, Katzenstein DA. 2001. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr 27:377-380.
28. Sonnerborg A, Johansson B, Ayehunie S, Julander I. 1993. Transmission of zidovudine-resistant HIV-1. AIDS 7:1684-1685.
29. Sugiura W, Matsuda Z, Yokomaku Y, Hertogs K, Larder B, Oishi T, Okano A, Shiino T, Tatsumi M, Matsuda M, Abumi H, Takata N, Shirahata S, Yamada K, Yoshikura H, Nagai Y. 2002. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 46:708-715.
30. Walmsley S, Bernstein B, King M. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346:2039-2046.
31. Yerly S, Rickenbach M, Popescu M, Taffe P, Craig C, Perrin L. 2001. Swiss HIV Cohort Study. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Antivir Ther 6:185-189.
32. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 131:813-821.